The solitary lymphomatous papule, nodule, or tumor - 19/08/11
Reprint requests: Madeleine Duvic, MD, Department of Dermatology, Box 0434, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030.Abstract |
Background |
Lymphoma and reactive lymphoid infiltrates presenting as solitary lesion pose a diagnostic and prognostic dilemma for the clinician.
Objective |
We sought to review prognosis and treatment of suggestive solitary lymphoma lesions.
Methods |
A retrospective chart review was conducted in 27 patients who presented with a single solitary lesion suggestive of lymphoma at a cancer center.
Results |
Eighteen of 27 patients’ (66.7%) lesions were diagnosed as lymphoma by histology and the remainder was classified as reactive lymphoid infiltrates. Only one patient’s lymphoma was systemic at presentation and one progressed later. In all, 23 patients (85.2%) subsequently experienced prolonged, complete remissions. The treatments used varied from none or conservative to chemotherapy, with the more aggressive treatments directed especially against lymphomas or recurrent diseases.
Limitations |
This study is limited by the number of patients and follow-up duration (average 36.8 months, range 3-133 months).
Conclusion |
Patients presenting with a solitary lesion suggestive of lymphoma and negative staging work-up results generally have a good prognosis. Excellent prognosis is usually expected for benign lesions.
Le texte complet de cet article est disponible en PDF.Abbreviations used : ALCL, CCR, CLH, CLL, CR, DLBCL, EORTC, MF, PR, PTCL-U, TCR, WHO
Plan
| Supported in part by the National Cancer Institute (CA 16672), Cancer Center (K24-CA 86815), and Sherry L. Anderson CTCL Research Fund (Dr Duvic). |
|
| Conflicts of interest: None declared. |
Vol 57 - N° 6
P. 1072-1083 - décembre 2007 Retour au numéro
Article précédent
- November Iotaderma (#166)
- Robert I. Rudolph
- Infantile bullous pemphigoid treated with intravenous immunoglobulin therapy
- Nobuyuki Sugawara, Yayoi Nagai, Yoichiro Matsushima, Kumi Aoyama, Osamu Ishikawa
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?